医脉通 20260122 摘要 医脉通拥有超过 700 万注册用户，其中执业医师占比超过 88%，2025 年上半年月活跃用户数达 278 万，显示其在中国医生群体中的高渗透率 和活跃度，为药企精准学术教育推广奠定基础。 医脉通通过前期调研、医生画像分析、医学素材加工和效果评估，为药 企提供精准学术教育服务，相较传统线下推广，提高了效率并节省了成 本，已覆盖 506 个产品，平均每个产品收入贡献约 100 万，未来增长 潜力巨大。 医脉通在 AI 应用方面整合了大量版权数据和医生用户行为数据，技术人 员具备丰富的医疗领域经验，已形成良性的商业化变现能力，能够持续 投入研发并实现商业化落地。 医脉通对临床指南、疾病知识库及文献网等产品进行了 AI 技术升级，实 现了从检索模式到智能问答模式的升级，日均调用频次提升 20%以上， 显著提升了医生用户的使用体验和效率。 2025 年下半年，医脉通开始与药企合作推出 AI 服务模块，如内容生成 与审核，并已开始带来收入，未来将根据客户需求不断拓展服务，但目 前客户需求还不够成熟和完善。 Q&A 目前医脉通有哪些 AI 相关产品已经落地？ 在服务医生方面，自 2025 ...

医脉通 20260121 摘要 医脉通拥有高质量的专业医学内容和中国医生行为数据，通过自有医学 编辑团队与行业专家合作，积累了医生基础画像、行为标签和对医学内 容的反馈，为 AI 模型训练提供宝贵资源。 医脉通已在医生端推出临床指南、疾病知识库、医学文献网等智能产品， 并计划上线 AI 智能问答工具和综合性智能体，满足医生临床问题解决和 科研报告撰写等需求。 医脉通通过大模型技术提升药企学术推广内容投放效率和精准度，并推 出专业医学内容审核和生成服务模块，按调用量收费，已与药企开展合 作并实现收入。 医脉通 2025 年经营性净利润率达到 21%，剔除利息收入后仍超过 20%，良性的商业化变现模式支撑公司持续投入技术研发和人员培养， 保持竞争优势。 医脉通的 AI 相关收入预计从 2025 年下半年开始体现，主要来自药企支 付的医学内容生成和审核等业务，属于药企营销预算的一部分，未来将 关注并挖掘药企需求。 Q&A 医脉通在 AI 应用领域的优势有哪些？ 医脉通在 AI 应用领域的优势主要体现在数据、技术和商业化变现能力三个方面。 首先，在数据方面，医脉通拥有丰富且专业的医学信息资源，包括行业内的指 南、共识 ...

Core Viewpoint - The AI healthcare sector in Hong Kong is experiencing a strong bullish trend, driven by clear industry trends and significant market demand for AI health solutions [1] Group 1: Market Performance - Alibaba Health has surged over 13%, leading the market with a cumulative increase of over 46% this month [1] - Other notable performers include Yidu Tech with a rise of over 9%, MicroPort Robotics up by 8.9%, and Ping An Good Doctor increasing by over 4% [1] - Additional companies such as Yimaitong, JD Health, and Gushengtang also saw gains [1] Group 2: Industry Drivers - The launch of Ant Group's AI health assistant "Antifufu" has seen monthly active users exceed 30 million, with daily inquiries surpassing 10 million, indicating strong demand in the health AI sector [1] - OpenAI's introduction of "ChatGPT Health" on January 8 further emphasizes the confidence of leading AI companies in the health AI market [1] Group 3: Market Forecast - Frost & Sullivan predicts that China's "AI + healthcare" market will grow from 8.8 billion yuan in 2023 to 315.7 billion yuan by 2033, with a compound annual growth rate of 43.1% over the next decade [1] - Huafu Securities reports that the AI healthcare industry is entering a critical phase of commercialization, supported by national strategies and market demand [1] - The report highlights a closed-loop demand for AI applications, which will sustain the continuous development of the AI industry [1]

Core Viewpoint - The recent surge in Hong Kong's AI healthcare stocks is driven by a clear confirmation of industry trends, with significant growth in user engagement and market potential for AI applications in healthcare [1][3][6] Group 1: Stock Performance - Alibaba Health has seen a rise of over 15%, with a cumulative increase of over 49% in January [1][6] - Other notable performers include Yidu Tech (up over 9%), MicroPort (up over 8%), Ping An Good Doctor (up over 5%), and JD Health (up over 2%) [1][6] Group 2: Market Analysis - The launch of Ant Group's AI health assistant "Antifufu" has resulted in over 30 million monthly active users and over 10 million daily inquiries, indicating strong demand in the health AI sector [3][8] - OpenAI's introduction of "ChatGPT Health" further emphasizes the confidence of leading AI companies in the health AI market [3][8] Group 3: Market Forecast - Frost & Sullivan predicts that China's "AI + healthcare" market will grow from 8.8 billion yuan in 2023 to 315.7 billion yuan by 2033, with a compound annual growth rate of 43.1% over the next decade [3][8] - Huafu Securities reports that the AI healthcare industry is entering a critical phase of commercialization, supported by national strategies and market demand [3][8] Group 4: Industry Innovation - Huachuang Securities anticipates that advancements in AI model capabilities will lead to comprehensive integration of AI in the healthcare industry, driving technological innovation [3][8] - The reduction in computing costs is expected to accelerate investments in AI capabilities by leading companies in various healthcare segments, potentially leading to a period of robust industry growth [3][8]

Core Viewpoint - The AI healthcare concept stocks experienced significant gains in the afternoon trading session, indicating a positive market sentiment towards this sector [1][4]. Stock Performance Summary - Ark Health (06086) saw a remarkable increase of 52.74%, rising by 3.62 HKD [1][4]. - Crystal Tech Holdings (02228) rose by 5.17%, reaching a price of 13.62 HKD [1][4]. - Yimaitong (02192) increased by 4.94%, with a current price of 13.80 HKD [1][4]. - Alibaba Health (00241) experienced a gain of 2.52%, trading at 6.52 HKD [1][4]. - iFlytek Medical Technology (02506) saw a modest increase of 1.30%, priced at 109.10 HKD [1][4].

Group 1 - The core viewpoint of the news is that AI healthcare concept stocks are experiencing significant gains, driven by a partnership between Nvidia and Eli Lilly to invest $1 billion in a joint research lab to accelerate AI applications in the pharmaceutical industry [1][2] - Ark Health (06086) saw a rise of 30.8%, while other AI healthcare stocks like Medical Pulse (02192) and Crystal Technology Holdings (02228) also reported increases of 5.1% and 4.63% respectively [1] - The joint lab established by Nvidia and Eli Lilly aims to generate large-scale data and build AI models to enhance new drug development, with operations expected to start early this year [1] Group 2 - According to Fengzheng Securities, AI-driven healthcare is forming a new growth engine, with a positive outlook on the revolutionary potential of AI in pharmaceuticals, basic research, diagnosis, and health management [2] - Huafu Securities noted that the AI healthcare industry has entered a critical stage of commercialization, supported by national strategies and market demand, with a closed-loop demand for AI applications sustaining the sustainable development of the AI industry [2]

Core Viewpoint - The company, 医脉通 (02192), announced the issuance of a total of 930,000 ordinary shares on January 5, 2026, as part of its pre-IPO share option plan adopted on March 29, 2021 [1] Group 1 - The company will issue 700,000 ordinary shares to two directors exercising their share options [1] - An additional 230,000 ordinary shares will be issued to one employee exercising their share options [1]

智通财经APP讯，医脉通(02192)发布公告，2026年1月5日，根据本公司于2021年3月29日采纳的首次公 开发售前购股权计划向行使购股权的本公司两位董事于2026年1月5日发行70万股普通股;根据本公司于 2021年3月29日采纳的首次公开发售前购股权计划向行使购股权的本公司一位员工于2026年1月5日发行 23万股普通股。 ...

此外，根据公司于2021年3月29日采纳的首次公开发售前购股权计划向行使购股权的公司一位员工于 2026年1月5日发行23万股普通股。 格隆汇1月5日丨医脉通(02192.HK)发布公告，根据公司于2021年3月29日采纳的首次公开发售前购股权 计划向行使购股权的公司两位董事于2026年1月5日发行70万股普通股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫脈通科技有限公司 呈交日期： 2026年1月5日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | | 02192 | 說明 | 普通股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 事件 | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發 ...